



PRESS RELEASE

Published: 25-05-2023

Inhalation Sciences receives 125,000 EURO funding in cross-European research project on inhaled antibiotics and antibiotic resistance

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125 000 EURO for its role in the research project ‘New Inhalation Formulations for Improved Delivery of Antimicrobials’ (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).

The unmet need for a targeted, efficacious inhaled antibiotic treatment for the growing number of patients hospitalized with lower respiratory tract infections (LRTIs) has become increasingly clear following the Covid-19 pandemic. The APRINHA project aims to address that unmet need. It will develop new inhaled formulations of an antibiotic that can both treat LRTIs and help reduce antibiotic resistance. The new formulations aim to improve drug deposition, retention, and penetration.

The project will last 36 months. Seven organizations are part of the consortium taking part, including RISE, the Research Institute of Sweden. All bring outstanding expertise in inhalation and pulmonary drug delivery with strong track records in contributing to multidisciplinary cross-border research projects. In this project, ISAB will collaborate with the inhalation team at RISE and be using its *in vivo* PreciseInhale equipment in RISE research facilities to carry out pharmacokinetic (PK) studies of the new formulations.

Manoush Masarrat, CEO ISAB: “We are pleased to be playing a part and would like to thank the team at the Institute of Medical Microbiology at UZH for initiating and coordinating the project. The unmet need for better formulations of antibacterial inhalation products that are active against drug-resistant respiratory infections is urgent. This project addresses that need.”

Read ISAB’s June 9 2022 Press Release on its joint funding proposal to APRINHA with RISE [here](#).

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on May 25, 2023.